Eris Lifesciences transfers 100% stake in 2 arms to Eris Therapeutics for Rs 861.9 crore
Ahmedabad: Eris Lifesciences has announced that the Company has transferred 100 percent of its holdings in two wholly-owned subsidiaries to Eris Therapeutics Limited, a wholly-owned subsidiary for Rs 861.9 crore. The transfer is a part of Eris Groups’ internal structuring of the holdings.
The two subsidaries are Eris Oaknet Healthcare Private Limited and Aprica Healthcare Limited.
The agreement for the transfer was entered on March 6, 2025 and expected date of completion of sale/disposal is March 31, 2025.
Read also: Eris Lifesciences ropes in Murari Ranganathan as President, Cardiometabolic Business
Established in 2007, Eris is a publicly listed Indian pharma company and is a leading player in the domestic branded formulations market. With an annual branded formulations revenue of INR 3,000+ crore as per AWACS, Eris has built a diversified presence across specialties and super-specialties such as Diabetes, Cardiovascular, Dermatology, Nephrology, Neurology, Women’s Health, Oncology and Critical Care. Eris manufactures a wide range of prescription products across several dosage forms including oral solids, oral liquids, softgels, ointments, sprays & gels, sterile injectables and biologics in its 6 manufacturing facilities, and markets these products across India through a network of 2,000+ stockists and 5,00,000+ retail pharmacies.
Eris’ operating revenue and profits have doubled in the last 5 years. The company has diversified its presence across geographies, technologies and therapeutic areas with an investment of ~ INR 4,000 crore over the last 3 years. For the first 9 months of financial year ending March 2025, the company reported a consolidated revenue of Rs 2,188 crore.
